Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

ClinicalTrials.gov lists 259 trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 13.

MeSH D056648 Cardiovascular Diseases C14 C17 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 51 Phase 1/2 Phase 1/2 15 Phase 2 Phase 2 37 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 34 Phase 4 Phase 4 22 Not applicable Not applicable 17 Observational Observational 77 Phase 1 Phase 1 51 Phase 1/2 Phase 1/2 15 Phase 2 Phase 2 37 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 34 Phase 4 Phase 4 22 Not applicable Not applicable 17 Observational Observational 77

Trials per phase

153 of the 259 trials are tagged with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis itself; the rest are tagged with a narrower condition beneath it.

Get the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 37

1990: 1 trials (Phase 2 1) 1995: 3 trials (Observational 1, Phase 2/3 1, Phase 1 1) 1996: 3 trials (Observational 1, Phase 4 2) 1997: 1 trials (Observational 1) 1998: 3 trials (Phase 2/3 1, Phase 1 2) 1999: 2 trials (Phase 3 1, Phase 2 1) 2000: 4 trials (Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 1) 2001: 2 trials (Phase 3 1, Phase 1/2 1) 2002: 3 trials (Phase 2 2, Phase 1 1) 2003: 5 trials (Phase 4 1, Phase 3 1, Phase 2 2, Phase 1 1) 2004: 2 trials (Not applicable 1, Phase 3 1) 2005: 2 trials (Phase 4 1, Phase 2/3 1) 2006: 2 trials (Observational 2) 2007: 3 trials (Phase 2 2, Phase 1/2 1) 2008: 5 trials (Phase 4 1, Phase 3 2, Phase 2 1, Phase 1/2 1) 2010: 4 trials (Observational 2, Not applicable 1, Phase 3 1) 2011: 6 trials (Observational 3, Phase 4 1, Phase 3 1, Phase 2 1) 2012: 7 trials (Observational 5, Phase 3 1, Phase 2 1) 2013: 6 trials (Observational 2, Phase 3 2, Phase 2 2) 2014: 14 trials (Observational 5, Not applicable 1, Phase 4 2, Phase 3 3, Phase 2 2, Phase 1 1) 2015: 15 trials (Observational 8, Phase 4 2, Phase 3 3, Phase 2 1, Phase 1 1) 2016: 6 trials (Observational 2, Phase 4 1, Phase 3 1, Phase 1 2) 2017: 4 trials (Observational 2, Phase 3 1, Phase 1 1) 2018: 10 trials (Observational 2, Not applicable 2, Phase 3 2, Phase 2 3, Phase 1 1) 2019: 10 trials (Observational 1, Not applicable 2, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 1) 2020: 9 trials (Observational 6, Not applicable 1, Phase 4 1, Phase 3 1) 2021: 6 trials (Observational 4, Not applicable 1, Phase 4 1) 2022: 13 trials (Observational 7, Not applicable 1, Phase 3 2, Phase 2 1, Phase 1/2 1, Phase 1 1) 2023: 14 trials (Observational 3, Phase 4 3, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 3) 2024: 30 trials (Observational 7, Not applicable 3, Phase 4 2, Phase 2 3, Phase 1/2 4, Phase 1 11) 2025: 37 trials (Observational 8, Not applicable 2, Phase 4 2, Phase 3 4, Phase 2 4, Phase 1/2 1, Phase 1 16)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 24
2025 37
2024 30
2023 14
2022 13
2021 6
2020 9
2019 10
2018 10
2017 4

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 31 trials starting in 2026 and about 33 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 56 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 101 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 51
Phase 1/2 15
Phase 2 37
Phase 2/3 6
Phase 3 34
Phase 4 22
Not applicable 17
Observational 77

How many Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 17
Recruiting 71
Enrolling by invitation 2
Active, not recruiting 17
Completed 92

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 13
Amgen 9
China Immunotech (Beijing) Biotechnology Co., Ltd. 6
GlaxoSmithKline 6
Nanjing Bioheng Biotech Co., Ltd. 6

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 30
Cytoxan 22
Prednisone 11
Avacopan 10
METHYLPREDNISOLONE 6

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Azathioprine Pill 15
Mepolizumab SC 14
Glucocorticoids 7
YTS109 cell 6
Mofetil Mycophenolate 6

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Infection 250 1
Other 168 1
Cardiovascular 124 1
Renal 77 1
Gastrointestinal 73 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis? (104)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide. RMD open 2025 Yes
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Annals of the rheumatic diseases 2024 Yes
Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study. Annals of the rheumatic diseases 2024 Yes
Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. Annals of the rheumatic diseases 2024 Yes
Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial. Annals of the rheumatic diseases 2024 Yes

Showing 5 of 104 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (12)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Anti-neutrophil cytoplasmic antibody-associated vasculitis Annual incidence 1-9 / 100 000 United States US Unspecified
Anti-neutrophil cytoplasmic antibody-associated vasculitis Point prevalence 1-5 / 10 000 United States US Unspecified
Anti-neutrophil cytoplasmic antibody-associated vasculitis Point prevalence 1-5 / 10 000 United States US Exact
Anti-neutrophil cytoplasmic antibody-associated vasculitis Annual incidence 1-9 / 100 000 United States US Exact
Anti-neutrophil cytoplasmic antibody-associated vasculitis Point prevalence 1-5 / 10 000 United States US Exact

Showing 5 of 12 prevalence observations.

Start your 14-day trial Email me all 12 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Anti-neutrophil cytoplasmic antibody-associated vasculitis 156152 Exact Orphanet Rare Disease Ontology (ORDO)
Anti-neutrophil cytoplasmic antibody-associated vasculitis 156152 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages